The FDA on May 17, 2016 granted accelerated approval to OPDIVO® for the treatment of patients with classical Hodgkin Lymphoma (cHL) that has relapsed or progressed after autologous Hematopoietic Stem Cell Transplantation (HSCT) and post-transplantation ADCETRIS® (Brentuximab vedotin). OPDIVO® is marketed by Bristol-Myers Squibb company
Other Pages – Bottom Ad
Advertisement
Subscribe
